Moomoo AI 已提取核心信息
Janus Henderson Group plc, an investment firm based in Jersey, Channel Islands, has filed an amended Schedule 13G/A with the United States Securities and Exchange Commission on February 12, 2024, indicating that they now own less than 5% of Altimmune, Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reflects a change in ownership status as Janus Henderson's managed portfolios no longer hold a significant stake in Altimmune's common stock. The shares were held by Janus Henderson's subsidiaries, including Janus Henderson Investors U.S. LLC, Janus Henderson Investors UK Limited, and Janus Henderson Investors Australia Institutional Funds Management Limited, which are collectively referred to as the Asset Managers. The Asset Managers are registered investment advisers that provide investment advice to various funds and clients. The filing emphasizes that the shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune.
Janus Henderson Group plc, an investment firm based in Jersey, Channel Islands, has filed an amended Schedule 13G/A with the United States Securities and Exchange Commission on February 12, 2024, indicating that they now own less than 5% of Altimmune, Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reflects a change in ownership status as Janus Henderson's managed portfolios no longer hold a significant stake in Altimmune's common stock. The shares were held by Janus Henderson's subsidiaries, including Janus Henderson Investors U.S. LLC, Janus Henderson Investors UK Limited, and Janus Henderson Investors Australia Institutional Funds Management Limited, which are collectively referred to as the Asset Managers. The Asset Managers are registered investment advisers that provide investment advice to various funds and clients. The filing emphasizes that the shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune.
总部位于海峡群岛泽西岛的投资公司Janus Henderson Group plc已于2024年2月12日向美国证券交易委员会提交了经修订的附表13G/A，表示他们现在拥有生物制药公司Altimmune, Inc. 不到5％的股份。该文件日期为2023年12月31日，反映了所有权状况的变化，因为骏利亨德森的管理投资组合不再持有Altimmune普通股的大量股份。这些股票由骏利亨德森的子公司持有，包括骏利亨德森投资美国有限责任公司、骏利亨德森投资英国有限公司和骏利亨德森投资澳大利亚机构基金管理有限公司，这些子公司统称为资产管理公司。资产管理公司是注册投资顾问，为各种基金和客户提供投资建议。该文件强调，这些股份是在正常业务过程中收购的，并不是为了改变或影响Altimmune的控制权。
总部位于海峡群岛泽西岛的投资公司Janus Henderson Group plc已于2024年2月12日向美国证券交易委员会提交了经修订的附表13G/A，表示他们现在拥有生物制药公司Altimmune, Inc. 不到5％的股份。该文件日期为2023年12月31日，反映了所有权状况的变化，因为骏利亨德森的管理投资组合不再持有Altimmune普通股的大量股份。这些股票由骏利亨德森的子公司持有，包括骏利亨德森投资美国有限责任公司、骏利亨德森投资英国有限公司和骏利亨德森投资澳大利亚机构基金管理有限公司，这些子公司统称为资产管理公司。资产管理公司是注册投资顾问，为各种基金和客户提供投资建议。该文件强调，这些股份是在正常业务过程中收购的，并不是为了改变或影响Altimmune的控制权。
有用
没用